Pharmacogenomic-based medication risk assessment in people with polypharmacy
- Resource Type
- Conference
- Authors
- Liu, Jiazhen; Zhu, Sinan; Finkelstein, Joseph
- Source
- 2017 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) Bioinformatics and Biomedicine (BIBM), 2017 IEEE International Conference on. :1489-1494 Nov, 2017
- Subject
- Bioengineering
Computing and Processing
Drugs
Biochemistry
Databases
Testing
Tools
Risk management
Prototypes
polypharmacy
pharmacogenomics
translational informatics
clinical decision support
- Language
Polypharmacy in older adults has been shown to be a significant risk factor for adverse drug events. Pharmacogenomic testing provides insights regarding individual drug efficacy and may be instrumental in optimizing medication regimen. However, majority of current pharmacogenomic decision support tools provide assessment only of single drug-gene interactions without taking into account complex drug-drug and drug-drug-gene interactions which are prevalent in people with polypharmacy and can result in adverse drug events or insufficient drug efficacy. The main objective of this project was to develop comprehensive pharmacogenomic decision support for medication risk assessment in people with polypharmacy that simultaneously accounts for multiple drug and gene effects. To achieve this goal, the project addressed two aims: (1) development of comprehensive knowledge repository of actionable pharmacogenes; (2) introduction of scoring approaches reflecting potential adverse effect risk levels of complex medication regimens accounting for pharmacogenomic polymorphisms and multiple drug metabolizing pathways. After pharmacogenomic knowledge repository was introduced, a scoring algorithm has been built and pilot-tested using a limited data set. The resulting total risk score for frequently hospitalized older adults with polypharmacy (72.04±17.84) was statistically significantly different (p